Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 4, 2007, Pages 1084-1089

  Martin, Jarad M ^a,b   Rosewall, Tara ^a   Bayley, Andrew ^a   Bristow, Robert ^a   Chung, Peter ^a   Crook, Juanita ^a   Gospodarowicz, Mary ^a   McLean, Michael ^a   Ménard, Cynthia ^a   Milosevic, Michael ^a   Warde, Padraig ^a   Catton, Charles ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Radiation Oncology Queensland   (Australia)

Author keywords

Conformal radiotherapy; Hypofractionation; Image guidance; Prostate carcinoma; Treatment toxicity

Indexed keywords

BIOCHEMICAL ENGINEERING; MEDICAL IMAGING; PATIENT MONITORING; RADIOLOGY; RADIOTHERAPY; TOXICITY;

CONFORMAL RADIOTHERAPY; HYPOFRACTIONATIONS; IMAGE GUIDANCE; PROSTATE CARCINOMA; THERAPEUTIC RADIOLOGY; TREATMENT TOXICITY;

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER STAGING; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FOLLOW UP; GLEASON SCORE; HUMAN; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RISK ASSESSMENT; TRANSRECTAL ULTRASONOGRAPHY;

ADENOCARCINOMA; AGED; BIOPSY; DOSE FRACTIONATION; FEASIBILITY STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; SALVAGE THERAPY;

EID: 35448944905     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.04.049     Document Type: Article

References (23)

1. Ferlay J, Bray F, Pisani P, Parkin D. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5., version 2.0. Available at: http://www-dep.iarc.fr/. Accessed April 24, 2006.
2. Pollack A., Smith L.G., and von Eschenbach A.C. External beam radiotherapy dose response characteristics of 1,127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 48 (2000) 507-512
3. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
4. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
5. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
6. Dearnaley D.P., Khoo V.S., Norman A.R., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 353 (1999) 267-272
7. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
8. Fowler J.F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncologica 44 (2005) 265-276
9. Kupelian P.A., Reddy C.A., Carlson T.P., et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 904-912
10. Kupelian P.A., Thakkar V.V., Khuntia D., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys 63 (2005) 1463-1468
11. Nichol A., Chung P., Lockwood G., et al. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. Radiother Oncol 76 (2005) 11-17
12. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
13. Lukka H., Warde P., Pickles T., et al. Controversies in prostate cancer radiotherapy: Consensus development. Can J Urol 8 (2001) 1314-1322
14. Wu J., Haycocks T., Alasti H., et al. Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother Oncol 61 (2001) 127-133
15. de Crevoisier R., Tucker S.L., Dong L., et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 965-973
16. Livsey J., Cowan R.A., Wylie J.P., et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis. Int J Radiat Oncol Biol Phys 57 (2003) 1254-1259
17. Pollack A., Hanlon A.L., Horwitz E.M., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64 (2006) 518-526
18. Ritter M.A., Chappell R.J., Fowler J.F., et al. A multi-institutional phase I/II trial of hypofractionated radiation therapy for localized prostate cancer. [Abstract]. In: Buckley D. (Ed). 2005 Multidisciplinary Prostate Cancer Symposium/Proceedings (2005), American Society of Clinical Oncology, Alexandria, VA 79
19. Pickles T., and British Columbia Cancer Agency Prostate Cohort Outcomes Initiative. Prostate-specific antigen (PSA) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calls? An analysis of 2,030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys 64 (2006) 1355-1359
20. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
21. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005) 6132-6138
22. Yeoh E.E., Holloway R.H., Fraser R.J., et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66 (2006) 1072-1083
23. Khoo V.S., Norman A.R., Syndikus I., et al. Randomized pilot study of conventional or hypofractionated high dose intensity modulated prostate radiotherapy (CHHIP)-acute toxicity report. [Abstract]. In: Buckley D. (Ed). 2005 Multidisciplinary Prostate Cancer Symposium/Proceedings (2005), American Society of Clinical Oncology, Alexandria, VA 79